Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2010, 28: 4953-4960. PMID: 20940188, PMCID: PMC4676802, DOI: 10.1200/jco.2010.30.8338.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseBenzoquinonesCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGene RearrangementHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicLung NeoplasmsMaleMiddle AgedMutationProspective StudiesProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesConceptsObjective response rateProgression-free survivalCell lung cancerIPI-504Lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor therapyUnited States cancer centersTyrosine kinase inhibitor therapyState Cancer CenterCommon adverse eventsLiver function abnormalitiesPhase II studyOverall study populationKinase inhibitor therapyHeat shock protein 90 inhibitorNovel heat shock protein 90 inhibitorALK gene rearrangementStable diseaseAdvanced NSCLCAdverse eventsFunction abnormalitiesII studyPartial responseInhibitor therapyPrimary outcome